anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Neoadjuvant anti-PD-1 therapy has shown encouraging efficacy in patients with deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer (LARC), which suggests its potential as a curative-intent therapy and a promising treatment option for organ preservation. We aimed to investigate the long-term outcomes of patients with dMMR/MSI-H LARC who experienced clinical complete response (cCR) after anti-PD-1 therapy.
METHODS: We retrospectively analyzed patients with dMMR/MSI-H LARC who achieved cCR and received nonoperative management following neoadjuvant anti-PD-1-based treatment from 4 Chinese medical centers. Patients were followed up for at least 1 year after they achieved cCR, their clinical data were collected, and survival outcomes were analyzed using the Kaplan-Meier method.
RESULTS: A total of 24 patients who achieved cCR and received nonoperative management from March 2018 to May 2022 were included, with a median age of 51.0 years (range, 19.0-77.0 years). The median treatment course to reach cCR was 6.0 (range, 1.0-12.0). Fifteen patients (62.5%) continued their treatments after experiencing cCR, and the median treatment course was 17.0 (range, 3.0-36.0). No local regrowth or distant metastasis was observed in a median follow-up time of 29.1 months (range, 12.6-48.5 months) after cCR. The 3-year disease-free and overall survivals were both 100%.
CONCLUSIONS: Patients with dMMR/MSI-H locally advanced or low-lying rectal cancer who achieved cCR following anti-PD-1-based therapy had promising long-term outcomes. A prospective clinical trial with a larger sample size is required to further validate these findings.
PROBLEM TO BE SOLVED: To provide a self-adhesive composite resin having excellent adhesiveness to dentine and mechanical strength and small polymerization contraction force.SOLUTION: The self-adhesive dental composite resin includes (A) 5-30 pts.wt. of a polymerizable monomer having an acidic group, (B) 1-30 pts.wt. of a long-chain polyfunctional polymerizable monomer having a structure expressed by general formula (I) and (C) 40-94 pts.wt. of a polymerizable monomer free from an acidic group and having a structure other than general formula (I) in 100 pts.wt. of total polymerizable monomers, and further contains (D) 100-900 pts.wt. of a filler based on 100 pts.wt. of the polymerizable monomers, and (E) a polymerization initiator. In the formula, R, R, Rand Rare each the same or different hydrogen atom or methyl; m and n are each an average addition molar number of oxyalkylene group; m+n is 20-40; and Ris either one of bivalent groups expressed by formula (A).
PURPOSE:To separate CSF effective to promote the differentiation and proliferation of myeloma cell of mammals, in high yield and purity from human urine. CONSTITUTION:Human urine is made to contact with a silicon-containing adsorbent [e.g. SiO2(H2O)n, etc.], and the adsorbed valuable substance is eluted with an alkaline solution of >=9pH. The eluate is made to contact with a cation exchange material under neutral condition to effect the adsorption and removal of impurities. The treated elutant is made to contact with an anion exchange material at 3.5-6pH to adsorb the valuable component to the ion exchange material, and the adsorbed component is eluted with 0.1-0.3M inorganic salt solution. The eluation process is repeated at 6-8pH. The elutant is adjusted to an inorganic salt concentration of 0.6-1.5M, made to contact with a hydrophobic affinity adsorbent at 6-8pH to effect the adsorption of the valuable component to said adsorbent, and eluted with a 0.4-0.15M inorganic salt solution. The elutant is brought into contact with a gel-filtration agent, and the fraction having a relative eluate volume of 1.1-1.7 to obtain high purity CSF.
INTRODUCTION: The photodynamic bone stabilization system (PBSS) was was developed in 2010, and in 2018 gained FDA approval in the United States. Given its relative novelty, our analysis sought to analyze the available literature exploring the indications, outcomes, and complications of the PBSS.
METHODS: We performed a systematic review (PROSPERO registration of study protocol: CRD42022363065, October 8th, 2022). PubMed, EBSCOHost, and Google Scholar electronic databases were queried to identify articles evaluating PBSS in the treatment of pathologic or traumatic fractures between January 1 2010 and 15 October 2022. The quality of the included studies was assessed using the Methodological Index for Nonrandomized Studies tool.
RESULTS: Our initial search yielded 326 publications, which were then screened for appropriate studies that aligned with the purpose of our review. A total of thirteen studies, comprising seven case series, four case reports, and two cohort studies. The total sample size of the included studies consisted of 345 patients, with 242 females (70%) and 103 males (30%). The implants were most commonly utilized in the humerus (41%), radius (12%), and metacarpal (12%). The most common complications were related to broken implants (5%) and dislocation (1%). Most studies reported complete fracture healing and return of full strength and range of motion.
CONCLUSION: Despite being a relatively novel technology, PBSS appears to be a viable option for fracture stabilization. Most studies included in our analysis reported complete fracture healing and return of function with minimal complications.
The evaluation of health risks among the public as a consequence of exposure to radioactive fallout from nuclear testing has been an important area of research for many years by investigators in the Radiation Epidemiology Branch (REB). As a result of the reputation of this group in the field of dose and risk assessment related to radioactive fallout, and the expertise of the National Cancer Institute (NCI) in cancer research, in 2007, U.S. Senator Jeff Bingaman (D, NM) sent a request to the NCI to evaluate the health risks to New Mexico residents from the first nuclear bomb test (named Trinity) that was conducted in 1945 in south-central New Mexico. The NCI responded in early 2008 with a preliminary evaluation of the radiation doses received by the residents of New Mexico. However, the evaluation made no special provisions for lifestyles and diets of tribal community members or Hispanics\\Latinos which were a significant part of the population. Little is known about Native American and Hispanic\\Latino lifestyles and diets in the mid-twentieth century, yet such data are necessary to produce a credible assessment of health risks to the state s population. For this reason, REB investigators did not publish the initial dose assessment in the peer-reviewed literature. Additionally, since statewide health records cannot be reconstructed in a meaningful way to determine excess disease rates, estimation of health risks in this population can only be projected (i.e., estimated) based on the magnitude and distribution of radiation doses received and the relationships between radiation dose and cancer risks observed in other populations. Since the preparation of the 2008 report, the REB exposure assessment models used to assess doses from radioactive fallout from other nuclear test sites have been improved and published in the peer-reviewed literature. The required improvements in the 2008 Trinity assessment that would support publication of the projected health risks includes sex- and age-dependent diet and lifestyle models for Native Americans and Hispanics\\Latinos in New Mexico in the mid-1940s. We are proposing a pilot study to collect, via individual interviews, information on lifestyle and diet from up to 9 key informants of Native Americans and Hispanics\\Latinos living in New Mexico who were alive at the time of the bomb (currently greater than or equal to 69 years old). This data will inform the design of a larger study, which will collect lifestyle and diet information from a series of targeted focus groups. The information acquired from these 9 individual interviews will be used to 1) determine the feasibility of assembling focus groups of members of tribal and Hispanic\\Latino communities in New Mexico who were alive in 1945 at the time of the bomb and 2) provide lifestyle and diet information to be used for refining focus group interviewing tools.
Exposure to stressful experiences accounts for almost half of the risk for mental disorders. Hence, stress-induced alterations represent a key target for pharmacological interventions aimed at restoring brain function in affected individuals. We have previously demonstrated that lurasidone, a multi-receptor antipsychotic drug approved for the treatment of schizophrenia and bipolar depression, can normalize the functional and molecular impairments induced by stress exposure, representing a valuable tool for the treatment of stress-induced mental illnesses. However, the mechanisms that may contribute to the therapeutic effects of lurasidone are still poorly understood. Here, we performed a transcriptomic analysis on the prefrontal cortex (PFC) of adult male rats exposed to the chronic mild stress (CMS) paradigm and we investigated the impact of chronic lurasidone treatment on such changes. We found that CMS exposure leads to an anhedonic phenotype associated with a down-regulation of different pathways associated to neuronal guidance and synaptic plasticity within the PFC. Interestingly, a significant part of these alterations (around 25%) were counteracted by lurasidone treatment. In summary, we provided new insights on the transcriptional changes relevant for the therapeutic intervention with lurasidone, which may ultimately promote resilience.
All of the study procedures will be completed over ten weeks, during which participants will complete one in-person enrollment visit per intervention and check in-phone calls as needed during the duration of each intervention. Participants will be randomly assigned in a 1:1 fashion to one of two different interventions first: virtual reality or Mp4 audio. At home, participants will engage in their assigned intervention 5x throughout the week for five weeks using the provided device and fill out required questionnaires. Once participants complete their first intervention, they will begin the second intervention.

In the virtual reality intervention, participants will complete the scheduled educational module five times in each of the five weeks. This VR is assisting users in using immersive reality to reduce pain, learning cognitive and behavior self-coping skills and retraining the pain pathways. There are several sessions, which will be delivered using an all-in-one head-mounted display. Each session varies in duration approximately from 3 to 15 minutes. Similarly, in the audio intervention, participants will complete the scheduled module 5 times a week in each of the five weeks of the intervention. The content is similar to that of the VR, which will be delivered by the audio player. Each session varies in duration approximately from 3 to 15 minutes.

The first visit is an enrollment visit. For the enrollment visit, the participant will first complete a battery of baseline surveys. They will also receive instructions about the intervention and go through the first module of the intervention to which he or she is assigned. A member of the research team will stay with the participant while the participant completes the module to ensure the proper functioning of the device and will answer any questions that may arise. The team member will also guide the participant on how to use the device. During the five weeks of the intervention, each participant can have check-in phone calls as needed. During these check-ins, we will address any questions and issues that arise for participants to encourage compliance. Participants will return the devices after each intervention.
Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
Participants in the oxytocin induction group received oxytocin induction during labour. The ALPS-Neo form was completed between 1-40 minutes after delivery, based on observation before, during and after the drying process, the first injection process and the blood glucose measurement procedures.
PURPOSE: To make it possible to change a fine hole size as required to offer a high flow velocity therein capable of removing the very fine particles like virus particles, by mixing fibrinogen solution into coagulated enzyme under the coagulation factors pre-adjusted to coagulate a so-obtained mixture in a mold for filtering material. CONSTITUTION: This fibrin-gel, during or after a coagulation, has a higher strength than the gel itself, and is applied to the top surface of the gel intended to obtain. It is preferred that the fibrin-gel is strengthened by a shape keeper applied onto the both top/back surfaces. This shape keeper (reinforcing mesh) 3 takes a net form to be applied to the bottom/top in the mold into which the fibrinogen mixture is poured (flowed). This mixture is impregnated into the nets (small-porous material) 2, for instance, holding its surface at 10 micro-m to 5mm above the net. The meshes of the nets are made to 10 micro-m to 5mm, for instance, and the diameter of wires to be used as a shape keeper is made to 0.01-1.0mm, for instance.
* Do not mix or dilute PARSABIV prior to administration. The solution is clear and colorless. Inspect PARSABIV for particulate matter and discoloration prior to administration. Do not use PARSABIV vials if particulate matter or discoloration is observed.
  * PARSABIV is removed by the dialyzer membrane and must be administered after blood is no longer circulating through the dialyzer.
  * Administer PARSABIV by intravenous bolus injection into the venous line of the dialysis circuit after hemodialysis during rinse back or intravenously after rinse back.
    * Administer a sufficient volume of saline, e.g. 150 mL of rinse back, after PARSABIV injection into the dialysis tubing.
    * If PARSABIV is administered after rinse back, administer PARSABIV intravenously followed by at least 10 mL of saline flush.
The BD regimen included bortezomib 1.3 mg/m2 i.v. and dexamethasone 40 mg p.o. on days 1, 4, 8 and 11 of the 21 day cycle. This process was repeated for 2 cycles. After two cycles of BD therapy, the collection of peripheral blood stem cells (PBSC) should be completed within 4 weeks. Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. Patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
The enrollment of up to thirty subjects with severe native aortic valve stenosis who meet clinically approved indications for transcatheter aortic valve replacement. The primary objective evaluates performance and treatment effect of the use of the EMBLOK. A secondary objective of this study is to analyze the safety profile and the type of captured debris from the Emblok filter after TAVR. Due to the small sample size, the study is not powered to detect a reduction in actual stroke rates. However, the potential risk of stroke will be assessed based on neurological evaluations pre and post procedure. In addition, silent ischemic damage and cerebral embolic burden will be assessed using DW MRI studies.
Participants first started on 2 Interventions (Dose A-QD) in Cycle 1, with 10 mg Lenalidomide (Len) once daily and 50 mg Cyclophosphamide (Cyc) once daily; 25 mg Sunitinib (Sun) was added once daily as a 3rd Intervention (Dose B-QD) from Cycle 2 onwards. Doses were adjusted in subsequent cycles depending on toxicity, including incremental step downs to 5/25/12.5 mg Len/Cyc/Sun once daily (Dose C-QD) or once every other day (Dose C-QOD).
Infants in the UCDMC Neonatal Intensive Care Unit with no congenital or acquired diseases of the skin or cardiovascular system will be enrolled after informed consent has been obtained from their parents. This is an observational study with no intervention. Procedures: At enrollment, 2 weeks and 4 weeks of age, skin lipids will be collected using three methods. First two small pieces of blotting paper (2 cm x 2 cm) will be placed on the infant's skin, one on the left side of the abdomen just above the umbilicus and one on the left inner thigh. The blotting paper will be left in place for 15 seconds and then removed. Second, two adhesive discs will be placed on the skin, one just below the umbilicus and one on the right inner thigh. The discs will be left in place for 30 seconds and then removed. Third, two areas of skin, one on the right side of the abdomen just above the umbilicus and the other on the inner right thigh, will be gently swabbed with sterile cotton swabs (one for each location). The intent is to remove a thin layer of oil/lipid from the skin upon removal of the paper or the adhesive disc or with swabbing without disrupting the skin surface (similar to taking a fingerprint). Blood specimens will be obtained three times, each time 1 ml : once at enrollment, at 2 weeks and the last one at 4 weeks of age, to generate a plasma lipoprotein profile and size distribution (HDL, LDL, VLDL, total cholesterol). For infants that are fed expressed human milk, we will also obtain a sample of mother's milk for analysis of lipid profile (about 2 ml).
AUVELITY contains dextromethorphan. Concomitant use of AUVELITY with SSRIs or tricyclic antidepressants may cause serotonin syndrome, a potentially life-threatening condition with changes including altered mental status, hypertension, restlessness, myoclonus, hyperthermia, hyperreflexia, diaphoresis, shivering, and tremor [see Drug Interactions (7.1), Overdosage (10)].

The concomitant use of AUVELITY with MAOIs is contraindicated. In addition, do not initiate AUVELITY in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking AUVELITY discontinue AUVELITY before initiating treatment with the MAOI [see Contraindications (4), Drug Interactions (7)].

Prior to initiating AUVELITY, screen patients for use of other dextromethorphan-containing products [see Dosage and Administration (2.1)]. If concomitant use of AUVELITY with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. Discontinue AUVELITY and/or concomitant serotonergic drug immediately if the above symptoms occur, and initiate supportive symptomatic treatment.
PURPOSE:An antitumor agent, containing 1,3,5-triglycidoxybenzene or 2,4,6-triglycidoxy-1,3,5-triazine as an active constituent, and having improved antitumor activity. CONSTITUTION:An antitumor agent containing a compound expressed by the formula (X is C or N) as an active constituent. The mode of antitumor action of the above-mentioned compound is not elucidated in detail, but triglycidyl isocyanurate having the glycidyl groups is already known to have the inhibitory action on cellular mitotic division. The glycidyl groups seem likely to have great effect on the antitumor action. There are several stereoisomers in the compound expressed by the formula, and the stereoisomers can be used as a mixture thereof or in the form of a single isolated isomer. In case the ratio of prolonged life is used as an index for remedial effect of mice having transplanted cancerous cells, the effect on prolongation of life is clearly recognized in the mice in comparison with the control group.
OBJECTIVES: A retrospective study was conducted to compare gravity drainage and suction drainage after cervical laminoplasty.
PATIENTS AND METHODS: A total of 375 patients who underwent laminoplasty between January 2011 and December 2015 were engaged in this analysis. We investigated the patients' basic characteristics, drainage characteristics and postoperative complications.
RESULTS: During the initial 24 h after laminoplasty, the drainage volume in the suction drainage group was 177.31 ± 92.02 mL, and the drainage volume in the gravity drainage group was 133.33 ± 92.40 mL. The drainage volume showed significant difference (p < 0.01). The total drainage volume was 357.49 ± 195.16 mL and 250.16 ± 27.44 mL in the suction drainage group and gravity drainage group, respectively. The total drainage volume between the two groups was statistically different (p = 0.03). The postoperative Hb was significantly different between the gravity group and suction group on the first day after the operation (108.37 ± 23.92 mL vs. 87.32 ± 21.53 mL, p = 0.02). The number of patients required blood transfusion was significantly different between the two groups as well (p = 0.04). Two cases had symptomatic epidural hematomas (SEH) after laminoplaty. However, the occurrence of SEH among the two groups was not different significantly. Twelve patients had surgical site infection (SSI). Of these 12, nine had applied gravity drainage and three suction drainage. The rate of SSI was similar between the two groups (p = 0.71).
CONCLUSION: The initial 24 h' drainage volume and the total drainage volume increased significantly in the suction drainage group. The postoperative Hb was lower in the suction group than the gravity drainage group the first postoperative day. More patients needed blood transfusion if suction drainage was performed. The application of suction drainage cannot decrease the incidence of SSI and SEH after laminoplasty. Gravity drainage is recommended for laminoplasty.
The world's population is ageing at a rate unprecedented in human history. As the number of older people increases, so does the prevalence of lung disease in the elderly, making it essential to understand the pathophysiology of elderly patients with lung disease. Age-related changes in immune system function and lung parenchyma occur throughout a person's life. Immunosenescence refers to the tendency for innate and adaptive immunity to decline in the elderly. As we age, changes in the innate and adaptive immune systems can lead to dysregulation and reduced immune function. A low-level chronic inflammatory state is known as inflamm-aging and is driven by immunosenescence. This review discusses the role of immunosenescence and inflamm-aging in pulmonary diseases such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma, and lung infections. Understanding the different manifestations of lung diseases between the elderly and the young, finding new therapeutic sites, or improving clinical outcomes in hospitalized patients will provide clinicians with new ideas.